Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.9 -3.05 (-1.13%) Market Cap: 34.30 Bil Enterprise Value: 33.17 Bil PE Ratio: 0 PB Ratio: 1,063.60 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 01:40PM GMT
Release Date Price: $136.2 (-2.34%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good morning, everyone. Thanks for joining us at the Bank of America Health Care Conference. I'm Tazeen Ahmad, one of the senior biotech analysts here at the firm. It is my pleasure this morning to introduce our next presenting company, Alnylam. Speaking for Alnylam this morning is Chief Executive Officer, John Maraganore. John, good morning.

John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

Good morning, Tazeen. And good morning, everybody, on the call.

Tazeen Ahmad;John M. Maraganore
BofA Merrill Lynch, Research Division - VP

So we're going to be spending the next 30 minutes talking about all the exciting things happening at Alnylam. But maybe as a starter for anyone on the phone who may not be as familiar with your company, can you just give us a quick overview of the platform of Alnylam, some of your recent accomplishments? And we can go into some details of upcoming catalysts, if that works, John.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot